TherapeuticsMD Inc (NASDAQ:TXMD) – Oppenheimer lowered their FY2022 EPS estimates for TherapeuticsMD in a note issued to investors on Tuesday, October 15th. Oppenheimer analyst J. Olson now anticipates that the company will post earnings per share of $0.20 for the year, down from their prior forecast of $0.24. Oppenheimer currently has a “Buy” rating and a $9.00 target price on the stock. Oppenheimer also issued estimates for TherapeuticsMD’s FY2023 earnings at $0.43 EPS.
A number of other equities analysts have also recently issued reports on TXMD. BidaskClub raised TherapeuticsMD from a “sell” rating to a “hold” rating in a report on Wednesday, September 11th. Zacks Investment Research raised TherapeuticsMD from a “sell” rating to a “hold” rating in a report on Saturday. Noble Financial reaffirmed a “buy” rating and issued a $13.00 target price on shares of TherapeuticsMD in a report on Friday, September 27th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $13.00 target price on shares of TherapeuticsMD in a report on Wednesday, August 7th. Finally, Jefferies Financial Group lowered their target price on TherapeuticsMD from $4.00 to $3.00 and set a “hold” rating for the company in a report on Monday, July 15th. Three analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. TherapeuticsMD has a consensus rating of “Buy” and an average target price of $10.44.
TherapeuticsMD stock opened at $3.67 on Friday. TherapeuticsMD has a 52 week low of $1.82 and a 52 week high of $6.09. The stock has a fifty day moving average of $3.49 and a 200-day moving average of $3.25. The company has a debt-to-equity ratio of 24.29, a quick ratio of 4.99 and a current ratio of 5.17. The stock has a market capitalization of $902.17 million, a P/E ratio of -6.22 and a beta of 1.69.
TherapeuticsMD (NASDAQ:TXMD) last posted its quarterly earnings results on Tuesday, August 6th. The company reported ($0.19) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.01). TherapeuticsMD had a negative return on equity of 212.57% and a negative net margin of 913.07%. The business had revenue of $6.08 million for the quarter, compared to analyst estimates of $5.12 million. During the same period last year, the firm posted ($0.15) EPS. TherapeuticsMD’s quarterly revenue was up 60.0% on a year-over-year basis.
Several hedge funds have recently modified their holdings of TXMD. Moors & Cabot Inc. acquired a new stake in shares of TherapeuticsMD in the second quarter valued at about $25,000. Moloney Securities Asset Management LLC acquired a new stake in shares of TherapeuticsMD in the second quarter valued at about $27,000. Highland Private Wealth Management acquired a new stake in shares of TherapeuticsMD in the second quarter valued at about $28,000. H D Vest Advisory Services acquired a new stake in shares of TherapeuticsMD in the second quarter valued at about $34,000. Finally, Advisor Group Inc. increased its stake in shares of TherapeuticsMD by 73.2% in the second quarter. Advisor Group Inc. now owns 13,960 shares of the company’s stock valued at $36,000 after buying an additional 5,900 shares during the period. 77.99% of the stock is owned by institutional investors.
In related news, Director Angus C. Russell purchased 10,000 shares of the firm’s stock in a transaction dated Friday, August 23rd. The stock was bought at an average price of $2.77 per share, with a total value of $27,700.00. Following the completion of the purchase, the director now owns 93,500 shares in the company, valued at approximately $258,995. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Robert G. Finizio purchased 35,000 shares of the firm’s stock in a transaction dated Tuesday, August 20th. The stock was bought at an average cost of $2.74 per share, with a total value of $95,900.00. Following the purchase, the chief executive officer now owns 18,253,964 shares of the company’s stock, valued at approximately $50,015,861.36. The disclosure for this purchase can be found here. In the last ninety days, insiders acquired 170,549 shares of company stock valued at $493,167. Insiders own 18.91% of the company’s stock.
TherapeuticsMD Company Profile
TherapeuticsMD, Inc operates as a women's health care product company in the United States. The company's hormone therapy drug candidate is the TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil. Its preclinical projects include the development of TX-005HR, a topical progesterone cream; TX-006HR, an estradiol and progesterone topical cream to penetrate human skin; and TX-00THR and TX-0008HR, which are transdermal patch forms.
Featured Story: What is the CBOE Russell 2000® Volatility Index?
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.